Log In
Print this Print this

Elelyso, Uplyso, alfataliglicerase, taliglucerase alfa (formerly prGCD)

  Manage Alerts
Collapse Summary General Information
Company Protalix BioTherapeutics Inc.
DescriptionPlant cell-expressed recombinant form of human glucocerebrosidase (GCase)
Molecular Target Glucocerebrosidase (GBA) (GCase)
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationGaucher's disease
Indication DetailsTreat Gaucher's disease; Treat Type I Gaucher's disease; Treat Type I Gaucher's disease in pediatric patients
Regulatory Designation U.S. - Expanded Access (Treat Gaucher's disease);
U.S. - Fast Track (Treat Gaucher's disease);
U.S. - Orphan Drug (Treat Gaucher's disease);
U.S. - Special Protocol Assessment (Treat Gaucher's disease);
EU - Orphan Drug (Treat Type I Gaucher's disease);
Australia - Orphan Drug (Treat Gaucher's disease);
Canada - Standard Review (Treat Gaucher's disease)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today